Combined standard and novel immunosuppressive substances affect B-lymphocyte function.

[1]  T. Chiles,et al.  Protein kinase Cβ is critical for the metabolic switch to glycolysis following B-cell antigen receptor engagement. , 2012, The Biochemical journal.

[2]  N. Unterwalder,et al.  Effects of sotrastaurin, mycophenolic acid and everolimus on human B‐lymphocyte function and activation , 2012, Transplant international : official journal of the European Society for Organ Transplantation.

[3]  W. Lieberthal,et al.  Mammalian target of rapamycin and the kidney. I. The signaling pathway. , 2012, American journal of physiology. Renal physiology.

[4]  M. Ibraheim,et al.  Effective therapy for acute antibody-mediated rejection with mild chronic changes: case report and review of the literature. , 2012, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[5]  L. Castellano,et al.  CD28 Family and Chronic Rejection: “To Belatacept...and Beyond!” , 2012, Journal of transplantation.

[6]  M. Bagot,et al.  IL-10 producing regulatory B cells in mice and humans: state of the art. , 2012, Current molecular medicine.

[7]  R. Marcus,et al.  Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation. , 2012, Clinical nephrology.

[8]  K. Budde,et al.  Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  T. Seiwert,et al.  Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin , 2011, Head & neck.

[10]  E. Woodle,et al.  Early and Late Acute Antibody-Mediated Rejection Differ Immunologically and in Response to Proteasome Inhibition , 2011, Transplantation.

[11]  Y. Baba,et al.  The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production. , 2011, Immunity.

[12]  K. Budde,et al.  Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation , 2011, Expert opinion on drug metabolism & toxicology.

[13]  R. Colvin,et al.  Emerging role of B cells in chronic allograft dysfunction. , 2010, Kidney international. Supplement.

[14]  Sandra K. Wittmann,et al.  Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  M. Stegall,et al.  The (re)emergence of B cells in organ transplantation , 2010, Current opinion in organ transplantation.

[16]  N. Pallet,et al.  Bortezomib as the Sole Post‐Renal Transplantation Desensitization Agent Does Not Decrease Donor‐Specific Anti‐HLA Antibodies , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  R. Alloway,et al.  Proteasome Inhibitor-Based Primary Therapy for Antibody-Mediated Renal Allograft Rejection , 2010, Transplantation.

[18]  Ethan M Balk,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.

[19]  Xin Zhang,et al.  IL‐21 and IL‐10 have redundant roles but differential capacities at different stages of plasma cell generation from human germinal center B cells , 2009, Journal of leukocyte biology.

[20]  G. Rummel,et al.  Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes. , 2009, Journal of medicinal chemistry.

[21]  D. Nochy,et al.  Comparison of Combination Plasmapheresis/IVIg/Anti‐CD20 Versus High‐Dose IVIg in the Treatment of Antibody‐Mediated Rejection , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  O. Viklicky,et al.  Plasmapheresis and Intravenous Immunoglobulin in Early Antibody‐Mediated Rejection of the Renal Allograft: A Single‐Center Experience , 2009, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[23]  R. Alloway,et al.  Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection , 2008, Transplantation.

[24]  D. Roelen,et al.  Effects of Immunosuppressive Drugs On Purified Human B Cells: Evidence Supporting the Use of MMF and Rapamycin , 2008, Transplantation.

[25]  D. Segev,et al.  The Use of Antibody to Complement Protein C5 for Salvage Treatment of Severe Antibody‐Mediated Rejection , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  Andreas Radbruch,et al.  1,25‐dihydroxyvitamin D3 promotes IL‐10 production in human B cells , 2008, European journal of immunology.

[27]  K. Dahan,et al.  Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients. , 2007, Transplantation proceedings.

[28]  K. Smith,et al.  The Effect of Sirolimus Therapy on Vaccine Responses in Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[30]  L. Rostaing,et al.  Rituximab therapy for acute humoral rejection after kidney transplantation. , 2007, Transplantation.

[31]  M. Müllner,et al.  Immunoadsorption in Severe C4d‐Positive Acute Kidney Allograft Rejection: A Randomized Controlled Trial , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  S. Ji,et al.  Rescue therapy by immunoadsorption in combination with tacrolimus and mycophenolate mofetil for C4d-positive acute humoral renal allograft rejection. , 2006, Transplantation proceedings.

[33]  A. Lanzavecchia,et al.  Toll‐like receptor stimulation as a third signal required for activation of human naive B cells , 2006, European journal of immunology.

[34]  Zhi-Hong Liu,et al.  Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  D. Stablein,et al.  Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. , 2004, Journal of the American Society of Nephrology : JASN.

[36]  D. Rawlings,et al.  Protein kinase C family functions in B-cell activation. , 2004, Current opinion in immunology.

[37]  W. Land,et al.  Plasmapheresis in C4d‐positive Acute Humoral Rejection Following Kidney Transplantation: A Review of 4 Cases , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[38]  W. Khan,et al.  B cell receptor directs the activation of NFAT and NF-kappaB via distinct molecular mechanisms. , 2003, Experimental cell research.

[39]  M. Teitell,et al.  PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling , 2002, Nature Immunology.

[40]  R. Wood,et al.  1,25-Dihydroxyvitamin D3 increases the expression of the CaT1 epithelial calcium channel in the Caco-2 human intestinal cell line , 2001, BMC Physiology.

[41]  R. Colvin,et al.  Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. , 2001, Transplantation.

[42]  G. Opelz,et al.  A RANDOMIZED AND PROSPECTIVE STUDY COMPARING TREATMENT WITH HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN WITH MONOCLONAL ANTIBODIES FOR RESCUE OF KIDNEY GRAFTS WITH STEROID-RESISTANT REJECTION , 2001, Transplantation.

[43]  R. Colvin,et al.  Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. , 1998, Transplantation.

[44]  L. Glimcher,et al.  Two levels of help for B cell alloantibody production , 1996, The Journal of experimental medicine.

[45]  D. Charron,et al.  Differential regulation of mRNAs encoding protein kinase C isoenzymes in activated human B cells. , 1994, Human immunology.

[46]  W. Kolch,et al.  Expression of protein kinase C genes in hemopoietic cells is cell-type- and B cell-differentiation stage specific. , 1991, Journal of immunology.

[47]  P. Dyer,et al.  PLASMA EXCHANGE IN ACUTE RENAL ALLOGRAFT REJECTION , 1983 .

[48]  A. Disney,et al.  A controlled trial of plasmapheresis in the treatment of renal allograft rejection. , 1981, Transplantation.

[49]  C. Legendre,et al.  Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment. , 2010, Clinical transplants.

[50]  M. Everly.  A summary of bortezomib use in transplantation across 29 centers. , 2009, Clinical transplants.

[51]  O. Illoh,et al.  Impact of rituximab therapy for treatment of acute humoral rejection , 2009, Clinical transplantation.

[52]  V. Nickeleit,et al.  The classification and treatment of antibody-mediated renal allograft injury: where do we stand? , 2007, Kidney international.

[53]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[54]  M. Keogan,et al.  Plasmapheresis as rescue therapy in accelerated acute humoral rejection , 2003, Journal of clinical apheresis.

[55]  Giulio Nicita,et al.  GUIDELINES ON RENAL TRANSPLANTATION , 2003 .

[56]  J. Bluestone,et al.  Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. , 2001, Annual review of immunology.

[57]  Jean L. Heneghan,et al.  Treatment of antibody‐mediated accelerated rejection using plasmapheresis , 2000, Journal of clinical apheresis.

[58]  G. Frascà,et al.  Effects of plasmapheresis in renal transplant rejection. A controlled study. , 1985, Transactions - American Society for Artificial Internal Organs.

[59]  A. Ythier,et al.  Plasma exchange in early kidney graft rejection associated with anti-donor antibodies. , 1983, Nephron.

[60]  Rowan G. Walker,et al.  Nephrology Dialysis Transplantation Suppression of the Humoral Immune Response by Mycophenolate Mofetil , 2022 .